Peer Review History
| Original SubmissionJuly 17, 2019 |
|---|
|
PONE-D-19-20179 Sexual violence against migrants and asylum seekers. The experience of the MSF clinic on Lesvos Island, Greece. PLOS ONE Dear Ms BELANTERI, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Nov 03 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Lindsay Stark Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. You indicated that ethical approval was not necessary for your study. We understand that the framework for ethical oversight requirements for studies of this type may differ depending on the setting and we would appreciate some further clarification regarding your research. Could you please provide further details on why your study is exempt from the need for approval and confirmation from your institutional review board or research ethics committee (e.g., in the form of a letter or email correspondence) that ethics review was not necessary for this study? Please include a copy of the correspondence as an "Other" file. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Very interesting topic, there is little known about forced migration to Greece, a country affected by a very interesting economic crisis. The authors have conveyed the magnitude of sexual violence and the devastating effect it has on displaced people. A valuable contribution of this manuscript is the information on male and female survivors of sexual abuse. I have included my comments in an attached document Reviewer #2: Thank you so much for this piece, which I was extremely excited to read. I found it very interesting, as it contains valuable data re: profiles of SV survivors and their perpetrators. I would be eager to have these insights from MSF’s records in the public domain and I think the article could be an important contribution to our understanding of sexual violence in migration, despite the small sample size. I have a few specific notes and questions, then some global comments. Specific notes and questions: - It would be additionally valuable to identify any trends possible re: kinds of violence / perpetrators associated with different patient profiles – eg, what can we learn about who is at risk of what, where, from whom? As it is, the tables and discussion are largely static, with little analysis across data points. Data analysis would be strengthened by cross-sectional observations – eg, while noting that 23% of cases involved perpetrators known to victim, this could perhaps be disaggregated by national origin or kind of violence to better identify important situational trends and better understand disinclination to report to authorities, for example. - Terminology: How were terms defined and phrased during survey? What is “compelled rape” as compared to "rape"? What is “daily activity”? Was torture clearly defined and understood? (Eg, “beaten” v “tortured” and also rape as a form of torture?). My suspicion is that the intake or screening instrument was a relatively blunt, which is not uncommon. However, this limitation or any reflections would be valuable to discuss, as conflation or confusion around terms of sexual violence seems to be a common challenge for all of us. Also, it is unclear whether forms of SV considered included intimate partner violence or sexual exploitation (latter of which was mentioned in conclusion and listed as an “associated violence” though unclear how defined or understood by MSF patients.) IPV can involve sexual violence and of course can have serious physical and psychological sequelae as well. Moreover, data indicate that rates of IPV remain high in conflict periods as well as in the context of forced displacement – is this major form of harm accounted for here? And if not, why not? - I worry that lines 264-266 contain information that is not technically accurate. While it is true that medical evidence of vulnerability is helpful to an asylum-seeker ultimately, my understanding is that the vulnerability screening for migrants arriving in Greece is actually a pre-admissibility / procedural step that simply determines whether someone is exempt from the EU-Turkey deal, such that they would be permitted to apply for asylum in Greece. It is not technically part of the asylum application itself. This also matters because medical certification of vulnerability including sexual violence may be useful for protection purposes (eg, finding that one is exempted from Turkey bounce-back and can instead apply for asylum in Greece) without being legal relevant for a Convention-based claim for refugee protection (if the harm suffered or feared does not involve one’s country of origin, as seems to be the case with many migrants exploited and abused in transit.) I advise rewording after consultation with expert on Greek asylum process. - I am also not sure about lines 267-272. There are some conclusory theories / statements re: why # of SV reports from Congolese v. Cameroonian migrants may differ – some statements re: exposure to conflict increasing risk of SV but also theories about how relatively long stays in camp may contribute to willingness to disclose SV. Is there data to support this theory? It may well be true but it seems there are insufficient data to infer these relationships. One could also theorize that different =people have different tendencies towards disclosure, either at group or individual level, not related to time spent in a camp. - It may also be worth mentioning that medical certifications / records might be useful in proving torture cases or trafficking cases, not just asylum. (Though these forms of harm can also be the basis of an asylum claim.) - Do the authors have any thoughts re: relative numbers (215 cases reported between Sept 2017 – Jan 2018)? Are these among new arrivals or general camp population? And if general population, why think so low compared to 5000 residents? It might help to explain how many of the total Moria resident population (for example) the MSF team actually reached, which might account for the winnowing down to 215 SV survivors. At any rate, this all raises the crucial issue of disclosure of sexual violence and how barriers may differ among groups and individuals – the discussion section touches on underreporting and disclosure but does not fully develop theories on it that are grounded in the data. This may be difficult with the limited data available but if there is any qualitative material in MSF records that could shed light on decisionmaking re disclosure, that would be fascinating indeed. Global comments: I think the data presented are incredibly valuable and these findings should be shared. However, as noted above, it would help to have clarification of MSF’s work on Lesvos and how the intake questionnaire was administered and translated, so we can better gauge how well the terms were understood by the migrants themselves. Policy and practice recommendations seem extremely important, particularly re: a) provision of mental health support services, b) inclusion of male survivors in screening & support efforts, and c) false reliance on “safe countries” like Turkey and Morocco. To strengthen these points, more background info / explanation would be helpful. - Eg, re: the mental health impacts of sexual and gender-based violence, as well as whether any mental health assessment was done with this population as part of MSF activities. The recommendation is sound but comes from out of nowhere. - Eg, whether one sees higher rates reported among specific sub populations of patients (as in Afghan teens on the move, who received a degree of attention several years ago), which might indicate which men and boys are most vulnerable in what situations. - Eg, more context re: EU-Turkey deal and its bottlenecking impact on Greece, including the assumption that Turkey is a safe country for return and adjudication. It could help, for example, to explain the major migration routes – as well as the short distance between Lesvos and Turkey, which would explain how the vast majority of migrants on Lesvos came through Turkey. Cites to reported human rights abuses against migrants in Turkey would help make the point re: false reliance on safe third country policy. I would definitely welcome the eventual publication of these data and insights, as I think the data is so important and MSF’s crucial work on Lesvos warrants significant attention. However, to strengthen the piece, I do suggest a strengthening of the discussion section and close proofread and technical / stylistic edit by a native English speaker. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Kim Thuy Seelinger [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
PONE-D-19-20179R1 Sexual violence against migrants and asylum seekers. The experience of the MSF clinic on Lesvos Island, Greece. PLOS ONE Dear Dr. BELANTERI, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Vedat Sar, M.D. Academic Editor PLOS ONE Additional Editor Comments (if provided): Dear Ms.Belanteri Thank you for re-submitting your manuscript. Both reviewers see considerable merit in your study, however, one of the reviewers has still concerns you may address in a revision. We would be glad to see a re-revised version of this manuscript. Best regards, Vedat Sar,MD [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: I Don't Know Reviewer #3: N/A ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: No Reviewer #3: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes Reviewer #3: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: Thank you for the attentive revision. I am sincerely looking forward to seeing this piece in print. Article needs one more close proofread, however, as several typos remain (for example in lines 111, 217, 246). Reviewer #3: This topic is certainly timely and the work that the organization has done is admirable. But what this paper presents is less than a scholarly article and reads more like a research report -- and even then a somewhat limited one. There is a descriptive overview of this particular case and context but there is little that is drawn in terms of conclusions or steps for either corrective action, intervention or even suggestions for future study. There were many important findings that were mentioned in passing in the paper but not ever really followed up on. For example, the data suggests significant variance in the gender composition of survivors from what we commonly know, but this is not explored in greater detail. The percentage of survivors who were actually raped is also not commented upon other than briefly. The implication that so-called 'safe' countries are not safe at all was another avenue not followed. These are but a few. I am thus unable to recommend publication even though the topic is significant and it appears that the authors have already gone to some length to address earlier reviews. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: Yes: Kim Thuy Seelinger Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Sexual violence against migrants and asylum seekers. The experience of the MSF clinic on Lesvos Island, Greece. PONE-D-19-20179R2 Dear Dr. BELANTERI, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Vedat Sar, M.D. Academic Editor PLOS ONE Additional Editor Comments (optional): The authors addressed reviwers' requests. Reviewers' comments: |
| Formally Accepted |
|
PONE-D-19-20179R2 Sexual violence against migrants and asylum seekers. The experience of the MSF clinic on Lesvos Island, Greece. Dear Dr. Belanteri: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Vedat Sar Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .